IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (to...
- Autores:
-
Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/45014
- Acceso en línea:
- https://hdl.handle.net/10495/45014
- Palabra clave:
- Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| Summary: | ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (total IgE, sIgE, blood eosinophil, and FeNO) in the framework of severe asthma and assessed its ability to help us to choose the best biological therapy for each patient. Different scenarios (sensitivity analysis) were evaluated according to the biomarkers proposed for each biological therapy in 72 patients with type-2 severe asthma. Between 54.1% and 68% of patients could receive at least 2 different biological therapies and 34.7%-40.2% could receive any of the 3 types of therapies (anti-IgE, anti-eosinophil, anti-IL4). Biomarkers help to identify type-2 severe asthma but total IgE, sIgE, blood eosinophil, and FeNO are not enough to select 1 specific therapy. With the increasing arrival of new biological therapies, it is necessary to identify new biomarkers that allow us to improve our selection criteria for the best therapy for each patient or to construct a prediction rule. |
|---|
